Literature DB >> 28831745

The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States.

Bennett Levitan1, A Brett Hauber2, Marina G Damiano3, Ross Jaffe4, Stephanie Christopher5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28831745     DOI： 10.1007/s40271-017-0272-6

Source DB:  PubMed          Journal:  Patient        ISSN： 1178-1653            Impact factor:   3.883


× No keyword cloud information.
  9 in total

1.  A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.

Authors:  Holly L Peay; Ilene Hollin; Ryan Fischer; John F P Bridges
Journal:  Clin Ther       Date:  2014-05       Impact factor: 3.393

2.  Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project.

Authors:  Esther W de Bekker-Grob; Conny Berlin; Bennett Levitan; Karim Raza; Kalliopi Christoforidi; Irina Cleemput; Jana Pelouchova; Harald Enzmann; Nigel Cook; Mats G Hansson
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

3.  Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators.

Authors:  D Postmus; M Mavris; H L Hillege; T Salmonson; B Ryll; A Plate; I Moulon; H-G Eichler; N Bere; F Pignatti
Journal:  Clin Pharmacol Ther       Date:  2016-02-17       Impact factor: 6.875

4.  Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.

Authors:  Ilene L Hollin; Holly L Peay; John F P Bridges
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

5.  Incorporating patient-preference evidence into regulatory decision making.

Authors:  Martin P Ho; Juan Marcos Gonzalez; Herbert P Lerner; Carolyn Y Neuland; Joyce M Whang; Michelle McMurry-Heath; A Brett Hauber; Telba Irony
Journal:  Surg Endosc       Date:  2015-01-01       Impact factor: 4.584

6.  Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Authors:  M Rummel; T M Kim; F Aversa; W Brugger; E Capochiani; C Plenteda; F Re; P Trask; S Osborne; R Smith; A Grigg
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

7.  Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.

Authors:  Marieke G M Weernink; Catharina G M Groothuis-Oudshoorn; Maarten J IJzerman; Janine A van Til
Journal:  Value Health       Date:  2016-01-21       Impact factor: 5.725

8.  Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?

Authors:  Caroline M Vass; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

9.  Comparison of different approaches applied in Analytic Hierarchy Process - an example of information needs of patients with rare diseases.

Authors:  Frédéric Pauer; Katharina Schmidt; Ana Babac; Kathrin Damm; Martin Frank; J-Matthias Graf von der Schulenburg
Journal:  BMC Med Inform Decis Mak       Date:  2016-09-09       Impact factor: 2.796
  9 in total
  7 in total

1.  Symposium Title: Preference Evidence for Regulatory Decisions.

Authors:  Juan Marcos Gonzalez; F Reed Johnson; Bennett Levitan; Rebecca Noel; Holly Peay
Journal:  Patient       Date:  2018-10       Impact factor: 3.883

2.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

3.  Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study.

Authors:  Andrea Young; Devidas Menon; Jackie Street; Walla Al-Hertani; Tania Stafinski
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

4.  Advancing the Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation: A Summary Report of the Patient Preference Workshop.

Authors:  Heather L Benz; Ting-Hsuan Joyce Lee; Jui-Hua Tsai; John F P Bridges; Sara Eggers; Megan Moncur; Fadia T Shaya; Ira Shoulson; Erica S Spatz; Leslie Wilson; Anindita Saha
Journal:  Patient       Date:  2019-12       Impact factor: 3.883

5.  Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention.

Authors:  David J Mott; Laura Ternent; Luke Vale
Journal:  Eur J Health Econ       Date:  2022-06-18

Review 6.  Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.

Authors:  Juan Marcos Gonzalez
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

7.  Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs.

Authors:  Nigel S Cook; Julie Cave; Anke-Peggy Holtorf
Journal:  Front Med (Lausanne)       Date:  2019-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.